MONONUCLEAR COMPOUND BASED ON RUTHENIUM (III) WITH ANTITUMOR ACTIVITY

Mononuclear compound based on ruthenium (III) whose antitumour activity has proved to be selective against cancer cells with respect to healthy cells. This selective action is due to the fact that the complex is based on a specific organic ligand (2,2'-biimidazole) that facilitates its interaction with the DNA of cancer cells. In this way, it has been shown to reduce the proliferation and migration of breast, colon and gastric cancer, with a clear action against breast cancer of the TNA and/or luminal B subtype in particular. On the other hand, this ruthenium-based compound, compared to existing platinum-based compounds, is more robust and inert when it comes to reacting in biological processes, which gives it high stability, thus extending the useful life of this compound in the physiological environment and enhancing its activity.